Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer

Clinical Cancer Research

Volumn 14, Issue 9, 2008, Pages 2681-2689

  Brennan, Donal J ^a   Rexhepaj, Elton ^a   O'Brien, Sallyann L ^a   McSherry, Elaine ^a   O'Connor, Darran P ^a   Fagan, Ailís I ^a   Culhane, Aedín C ^c   Higgins, Desmond G ^a   Jirstrom, Karin ^a,c,d   Millikan, Robert C ^e   Landberg, Goran ^c   Duffy, Michael J ^a,b   Hewitt, Stephen M ^f   Gallagher, William M ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d LUND UNIVERSITY   (Sweden)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; MYC PROTEIN; PROGESTERONE RECEPTOR; PROTEIN P53; SURVIVIN; BIRC5 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ALGORITHM; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CELL NUCLEUS; CYTOPLASM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MEASUREMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; TISSUE MICROARRAY; BREAST TUMOR; FEMALE; METABOLISM; MIDDLE AGED; MORTALITY; REGRESSION ANALYSIS; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; CYTOPLASM; FEMALE; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; REGRESSION ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 50249145879     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1760     Document Type: Article

References (37)

1. Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM, Ryan BM. Survivin: a promising tumor biomarker. Cancer Lett 2007;249:49-60.
2. Velculescu VE, Madden SL, Zhang L, et al. Analysis of human transcriptomes. Nat Genet 1999;23:387-8.
3. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21.
4. Chu JS, Shew JY, Huang CS. Immunohistochemical analysis of survivin expression in primary breast cancers. J Formos Med Assoc 2004;103:925-31.
5. O'Driscoll L, Linehan R, Kennedy SM, et al. Lack of prognostic significance of survivin, survivin-δEx3, survivin-2B, galectin-3, bag-1, bax-α and MRP-1 mRNAs in breast cancer. Cancer Lett 2003;201: 225-36.
6. Tanaka K, Iwamoto S, Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000;6:127-34.
7. Kennedy SM, O'Driscoll L, Purcell R, et al. Prognostic importance of survivin in breast cancer. Br J Cancer 2003:88:1077-83.
8. Ryan BM, Konecny GE, Kahlert S, et al. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2,VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 2006;17: 597 -604.
9. Span PN, Sweep FC,Wiegerinck ET, et al. Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem 2004;50: 1986-93.
10. Hinnis AR, Luckett JC, Walker RA. Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer 2007; 96:639-45.
11. Paik S, Shak S.Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817 -26.
12. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
13. O'Brien SL, Fagan A, Fox EJ, et al. CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int J Cancer 2007;120:1426-35.
14. Li F, Yang J, Ramnath N, Javle MM, Tan D. Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 2005;114:509-12.
15. Svensson S, Jirstrom K, Ryden L, et al. ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene 2005;24: 4370-9.
16. Ryden L, Linderholm B, Nielsen NH, et al. Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat 2003;82:147-54.
17. Brennan DJ, Jirstrom K, Kronblad A, et al. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin Cancer Res 2006;12:6421 -31.
18. Roos G, Nilsson P, Cajander S, et al.Telomerase activity in relation to p53 status and clinico-pathological parameters in breast cancer. Int J Cancer 1998;79: 343-8.
19. Loden M, Stighall M, Nielsen NH, et al. The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene 2002;21:4680-90.
20. ShiT, Seligson D, Belldegrun AS, Palotie A, Horvath S. Tumor classification by tissue microarray profiling: random forest clustering applied to renal cell carcinoma. Mod Pathol 2005;18:547-57.
21. Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005;435:1262-6.
22. Brennan DJ, O'Brien SL, Fagan A, et al. Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response. Expert Opin Biol Ther 2005;5:1069-83.
23. Fernandez DC, Bhargava R, Hewitt SM, Levin IW. Infrared spectroscopic imaging for histopathologic recognition. Nat Biotechnol 2005;23:469-74.
24. Brennan DJ, Kelly C, Rexhepaj E, et al. Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer. Cancer Genomics Proteomics 2007;4:3-16.
25. Span PN, Tjan-Heijnen VC, Manders P, et al. High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer. Breast Cancer Res Treat 2006;98:223-30.
26. Knauer SK, Kramer OH, Knosel T, et al. Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J 2007;21:207-16.
27. Knauer SK, Mann W, Stauber RH. Survivin's dual role: an export's view. Cell Cycle 2007;6: 518-21.
28. Fortugno P.Wall NR, Giodini A, et al. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci2002;115:575-85.
29. Knauer SK, Bier C, Habtemichael N, Stauber RH. The survivin-Crm1 interaction is essential for chromosomal passenger complex localization and function. EMBO Rep 2006;7:1259-65.
30. Colnaghi R, Connell CM, Barrett RM, Wheatley SP. Separating the anti-apoptotic and mitotic roles of survivin. J Biol Chem 2006;281:33450-6.
31. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-4.
32. Sampath SC, Ohi R, Leismann 0, et al. The chromosomal passenger complex is required for chromatininduced microtubule stabilization and spindle assembly. Cell 2004;118:187-202.
33. Gassmann R, Carvalho A, Henzing AJ, et al. Borealin: a novel chromosomal passenger required for stability of the bipolar mitotic spindle. J Cell Biol 2004; 166:179-91.
34. Bolton MA, Lan W, Powers SE, et al. Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. Mol Biol Cell 2002;13: 3064-77.
35. Cappellen D, SchlangeT, Bauer M, Maurer F, Hynes NE. Novel c-MYC target genes mediate differential effects on cell proliferation and migration. EMBO Rep 2007;8:70-6.
36. Isola J.VisakorpiT, Holli K, Kallioniemi OP. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992;84:1109-14.
37. Barbareschi M, Leonardi E, Mauri FA, Serio G, Dalla Palma P. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am J Clin Pathol 1992;98:408-18.